Silevertinib

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H30ClFN6O2
Molecular Weight	561.05
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C[C@H]2C[C@]2(C1)C#CC3=CC4=C(C=C3NC(=O)\C=C\CN5CCOCC5)C(NC6=CC=CC(Cl)=C6F)=NC=N4

InChI

InChIKey=LMOVDLRMIRLIJF-TUVXKDNKSA-N

InChI=1S/C30H30ClFN6O2/c1-37-17-21-16-30(21,18-37)8-7-20-14-26-22(29(34-19-33-26)36-24-5-2-4-23(31)28(24)32)15-25(20)35-27(39)6-3-9-38-10-12-40-13-11-38/h2-6,14-15,19,21H,9-13,16-18H2,1H3,(H,35,39)(H,33,34,36)/b6-3+/t21-,30+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H30ClFN6O2
Molecular Weight	561.05
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	1
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 12:48:23 GMT 2025` Edited by `admin` on `Wed Apr 02 12:48:23 GMT 2025`
Record UNII	RP9F537KVY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Silevertinib

Official Name

English

BDTX-1535

Preferred Name

English

(E)-N-(4-((3-chloro-2-fluorophenyl)amino)-7-(((1R,5S)-3-methyl-3-azabicyclo[3.1.0]hexan-1-yl)ethynyl)quinazolin-6-yl)-4-morpholinobut-2-enamide

Systematic Name

English

silevertinib [INN]

Common Name

English

(2E)-N-[4-[(3-Chloro-2-fluorophenyl)amino]-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hex-1-yl]ethynyl]-6-quinazolinyl]-4-(4-morpholinyl)-2-butenamide

Systematic Name

English

EGFR-IN-76

Common Name

English

Code System Code Type Description

INN

13382

Created by admin on Wed Apr 02 12:48:23 GMT 2025 , Edited by admin on Wed Apr 02 12:48:23 GMT 2025

PRIMARY

CAS

2607829-38-7

Created by admin on Wed Apr 02 12:48:23 GMT 2025 , Edited by admin on Wed Apr 02 12:48:23 GMT 2025

PRIMARY

PUBCHEM

156071569

Created by admin on Wed Apr 02 12:48:23 GMT 2025 , Edited by admin on Wed Apr 02 12:48:23 GMT 2025

PRIMARY

FDA UNII

RP9F537KVY

Created by admin on Wed Apr 02 12:48:23 GMT 2025 , Edited by admin on Wed Apr 02 12:48:23 GMT 2025

PRIMARY

Related Record Type Details


					RP9F537KVY

Silevertinib

ACTIVE MOIETY

Comments:

BDTX-1535 is an orally available, adenosine triphosphate (ATP)-competitive, potent, kinome selective, irreversible, and brain penetrant inhibitor of amplified wild type-epidermal growth factor receptor (WT-EGFR) and EGFR mutations, including acquired drug resistance mutations (eg, C797S), uncommon EGFR mutations expressed in NSCLC (eg, G719C) and the group of allosteric EGFR mutant variants found in GBM (eg, EGFRvIII).

Amount: